LivePerson And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 75 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Cartesian Therapeutics
- The Trade: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Timothy A Springer acquired a total of 1,185,872 shares an average price of $0.56. To acquire these shares, it cost around $666,222.
- What’s Happening: On March 18, HC Wainwright & Co. analyst Mitchell Kapoor reiterated Cartesian Therapeutics with a Buy and maintained a $2 price target.
- What Cartesian Therapeutics Does: Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company.
Aware
- The Trade: Aware, Inc. (NASDAQ:AWRE) CEO and President Robert A Eckel acquired a total of 13,735 shares at at an average price of $1.67. To acquire these shares, it cost around $22,881.
- What’s Happening: On March 12, Aware reported a year-over-year decrease in fourth-quarter EPS results..
- What Aware Does: Aware Inc is a provider of software and services to the biometrics industry. The company's software products are used in government and commercial biometrics systems to identify or authenticate people.
Check This Out: Investor Optimism Decreases Ahead Of Fed Meeting; S&P Snaps 3-Session Losing Streak
LivePerson
- The Trade: LivePerson, Inc. (NASDAQ:LPSN) Director Vanessa Pegueros acquired a total of 5,000 shares at an average price of $1.02. The insider spent around $5,100 to buy those shares.
- What’s Happening: On Feb. 28, LivePerson reported mixed fourth-quarter financial results and issued 2024 total revenue guidance below estimates.
- What LivePerson Does: LivePerson Inc is the enterprise leader in digital customer conversation.
Don’t forget to check out our premarket coverage here